Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GEM-Ag-T
- Development stage
- Preclinical
- Lead developer
- Achelois Pharmaceuticals
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
GEM-Ag-T is an investigational, genetically modified antigen-specific T-cell therapy being developed by Achelois BioPharma for the treatment of rare solid tumors. The therapy is built upon Achelois's proprietary integrated platform, which combines APTC (Antigen-Presenting T-Cell) training, Ag-T (Antigen-specific T-cell) expansion, and GEM (Genetic Engineering Modification) technologies. This approach is designed to produce bespoke cellular immunotherapies that are specifically trained and genetically equipped to target tumor-associated antigens. As of early 2024, the GEM-Ag-T program for rare solid tumors is in the discovery and IND-enabling phase of development.
- Other names
- Ag-T-Achelois-T-cell therapy
02
Targets
pMHC-I (Peptide–MHC class I complex)
Beyond the preview
Go deeper on GEM-Ag-T.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GEM-Ag-T.